Research programme: cystic fibrosis transmembrane conductance regulator modulators - Galapagos/AbbVie

Drug Profile

Research programme: cystic fibrosis transmembrane conductance regulator modulators - Galapagos/AbbVie

Alternative Names: Cystic fibrosis therapy research programme - Cystic Fibrosis Foundation/Galapagos; GLPG-2665

Latest Information Update: 28 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Galapagos NV
  • Developer AbbVie; Galapagos NV
  • Class Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cystic fibrosis

Most Recent Events

  • 28 Jan 2018 No recent reports of development identified for preclinical development in Cystic-fibrosis in Belgium (PO)
  • 15 Oct 2015 Early research in Cystic fibrosis (Combination therapy) in Belgium (PO)
  • 15 Oct 2015 Pharmacodynamics data from in vitro studies in Cystic fibrosis released by Galapagos
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top